A Phase I/II, Double-Blind, Dose-Escalation Study to Evaluate the Safety and Antiviral Activity of IDX184 in Treatment-Naive Subjects Infected With Genotype 1 Chronic Hepatitis C.

Trial Profile

A Phase I/II, Double-Blind, Dose-Escalation Study to Evaluate the Safety and Antiviral Activity of IDX184 in Treatment-Naive Subjects Infected With Genotype 1 Chronic Hepatitis C.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 May 2015

At a glance

  • Drugs IDX 184 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Idenix Pharmaceuticals; Merck Sharp & Dohme
  • Most Recent Events

    • 15 Oct 2012 Results published in Antimicrobial Agents and Chemotherapy.
    • 13 Nov 2009 Planned end date changed from 1 May 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
    • 02 Nov 2009 Results have been presented at AASLD 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top